The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), American ...

In a report released on April 9, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly and ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

OrderlyMeds, a provider of compounded versions of GLP-1 weight loss drugs, including Eli Lilly’s (NYSE:LLY) tirzepatide, said on Friday that a cease-and-desist letter sent by the pharma giant would ...

Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who ...

In the long term, bariatric surgery is more cost-effective than new anti-obesity medications, research finds, triggering a ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...